Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Scientists finally discover how a common gut bacterium can trigger colon cancer | ScienceDaily (opens in a new tab)

sciencedaily.com · 2026-10-31

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of four claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 2 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe story says the team developed a soluble claudin-4-based molecular decoy that intercepted BFT and protected mice from the toxin's harmful effects.View evidenceHide evidence

Why this verdict

The abstract-level paper profile does not describe a soluble claudin-4 decoy, mouse protection experiments, or in vivo protection from toxin-induced injury. The only therapeutic material visible at this depth is an implication that receptor identification 'opens avenues' for anti-BFT therapies, with no abstract-described intervention testing. The story's causal mouse-protection claim therefore cannot be verified at the requested abstract depth.

1

Study evidence

Identification of claudin-4 as the BFT receptor is presented as enabling development of anti-BFT therapies (abstract language: "opens avenues for the development of anti-BFT therapies").

“opens avenues for the development of anti-BFT therapies”
Claim 2 of 4Not coveredThe article says the authors caution that the mouse experiments did not establish that the decoy strategy prevents colorectal cancer in humans.View evidenceHide evidence

Why this verdict

The abstract profile does not include mouse decoy experiments, human colorectal cancer prevention testing, or author cautions about such testing. The caution is directionally consistent with the abstract's limited therapeutic-implication framing, but the specific claim is not verifiable from the supplied abstract-depth profile.

1

Study evidence

Identification of claudin-4 as the BFT receptor is presented as enabling development of anti-BFT therapies (abstract language: "opens avenues for the development of anti-BFT therapies").

“opens avenues for the development of anti-BFT therapies”
Claim 3 of 4SupportedScientists at Johns Hopkins say they have found the missing step showing how a toxin from Bacteroides fragilis first attaches to intestinal cells and begins damaging the colon.View evidenceHide evidence

As statednearly two decades of uncertainty

Why this verdict

At abstract depth, the paper profile supports the core story framing that the receptor step was previously unknown and that the authors identify claudin-4 as the BFT receptor, with claudin-4 binding promoting BFT-mediated E-cadherin cleavage. The exact phrasing about 'nearly two decades' is not independently verifiable from the abstract profile, but the main 'missing link' receptor-mechanism claim is supported.

1

Study evidence

A genome-wide CRISPR screen identified claudin-4 as the BFT receptor; claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin.

“Here we identify claudin-4 as a BFT receptor through a genome-wide CRISPR screen”
2

Study evidence

Claudin-4 (CLDN4) was identified as a BFT receptor via a genome-wide CRISPR screen.

“demonstrate that claudin-4 binding promotes BFT-mediated cleavage of cell surface E-cadherin”
Claim 4 of 4SupportedThe article says the researchers identified claudin-4 as the essential docking point, or receptor, for the bacterial toxin BFT.View evidenceHide evidence

Why this verdict

The abstract profile directly states that the paper identifies claudin-4 as a BFT receptor through a genome-wide CRISPR screen and follow-up in vitro binding/validation assays. Calling claudin-4 the receptor or docking point is consistent with the supplied profile.

1

Study evidence

A genome-wide CRISPR screen identified claudin-4 as the BFT receptor; claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin.

“Here we identify claudin-4 as a BFT receptor through a genome-wide CRISPR screen”
2

Study evidence

Claudin-4 (CLDN4) was identified as a BFT receptor via a genome-wide CRISPR screen.

“demonstrate that claudin-4 binding promotes BFT-mediated cleavage of cell surface E-cadherin”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The mechanistic finding is that BFT binding to claudin-4 promotes cleavage of cell-surface E-cadherin, linked to epithelial barrier and cellular effects.

    The story broadly says the toxin begins damaging colon or intestinal cells, but the supplied presentation does not mention the specific E-cadherin cleavage mechanism that is a primary contribution in the paper profile.

    From in_vitro_binding_validation; in vitro cell-based toxin challenge and CLDN4 perturbation

  • At abstract depth, therapeutic development is framed as an implication of receptor identification, not as an abstract-described tested decoy or mouse intervention.

    The story presents a soluble claudin-4 decoy and mouse protection as empirical results, but the abstract-level paper profile only says the work opens avenues for anti-BFT therapies and explicitly lacks described blockade or therapeutic proof-of-concept experiments.

    From other

  • The paper profile's limitations include that quantitative results, controls, sample sizes, replication, statistical thresholds, and detailed assay parameters are unavailable at abstract depth.

    The story's caveats mention cancer risk, unresolved structural detail, mouse-to-human cancer prevention, and AI structure prediction, but they do not acknowledge the abstract-depth limitation that key quantitative and methodological validation details are not available in the supplied paper profile.

    From genome-wide CRISPR knockout screen; in_vitro_binding_validation; in vitro cell-based toxin challenge and CLDN4 perturbat

  • The paper profile cautions that the identified evidence is primarily in vitro and that generalizability and in vivo relevance require further confirmation at this evidence depth.

    This interpretation-changing limitation is not reflected in the supplied story presentation. Instead, the story asserts mouse protection experiments that are not verifiable in the abstract profile.

    From genome-wide CRISPR knockout screen; in_vitro_binding_validation; in vitro cell-based toxin challenge and CLDN4 perturbat

1 thing the story did carry across
  • The paper's central finding is identification of claudin-4 as the host-cell receptor for Bacteroides fragilis toxin.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroIdentify the host-cell receptor for Bacteroides fragilis toxin (BFT), establishing claudin-4 as the receptor.genome-wide CRISPR knockout screenExpand

In plain English

A genome-wide CRISPR knockout screen in epithelial cells identified claudin-4 as the cell-surface receptor for Bacteroides fragilis toxin (BFT); claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin.

Key findings

  • A genome-wide CRISPR screen identified claudin-4 as the BFT receptor; claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin.
“Here we identify claudin-4 as a BFT receptor through a genome-wide CRISPR screen”
What this piece can’t prove
  • Findings derive from cell-based (in vitro) screening and selection; generalizability and in vivo relevance need further confirmation.

2 further details could not be confirmed from the summary.

2in vitroIdentify the host-cell receptor for Bacteroides fragilis toxin (BFT), establishing claudin-4 as the receptor.in vitro binding validationExpand

In plain English

Using a genome-wide CRISPR screen and follow-up in vitro assays, the paper identifies claudin-4 (CLDN4) as a host-cell receptor for Bacteroides fragilis toxin (BFT) and reports that claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin.

Key findings

  • Claudin-4 (CLDN4) was identified as a BFT receptor via a genome-wide CRISPR screen.
  • In vitro assays demonstrate that BFT binds claudin-4 at the cell surface and that claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin.
“demonstrate that claudin-4 binding promotes BFT-mediated cleavage of cell surface E-cadherin”
What this piece can’t prove
  • Summary is constrained to the abstract: key experimental details, quantitative effect sizes, controls, and statistical support are not available here.

2 further details could not be confirmed from the summary.

3in vitroDemonstrate mechanistically that BFT binding to claudin-4 promotes cleavage of cell-surface E-cadherin and consequent epithelial effects.in vitro cell-based toxin challenge and CLDN4 perturbationExpand

In plain English

The paper reports that the Bacteroides fragilis toxin (BFT) binds claudin-4 and that claudin-4 binding promotes BFT-mediated cleavage of cell-surface E-cadherin; this cleavage is linked to epithelial barrier disruption and cellular responses associated with inflammation and proliferation. The claim is presented as mechanistic validation following identification of claudin-4 as a BFT receptor (genome-wide CRISPR screen).

Key findings

  • BFT exposure causes cleavage of the E-cadherin ectodomain on epithelial cells.
  • The cleavage of cell-surface E-cadherin by BFT depends on claudin-4: claudin-4 binding promotes BFT-mediated E-cadherin cleavage (demonstrated via perturbation/rescue experiments).
“BFT ... causes cleavage of the E-cadherin ectodomain”
What this piece can’t prove

4 further details could not be confirmed from the summary.

4otherProvide therapeutic/translation-enabling implications (e.g., anti-BFT strategies) based on receptor identification and mechanism.Expand

In plain English

The abstract reports identification of claudin-4 as the receptor for B. fragilis toxin (BFT) and states this finding "opens avenues for the development of anti-BFT therapies." The abstract does not describe any experiments testing blockade of the BFT–claudin-4 interaction or other therapeutic/inhibition strategies.

Key findings

  • Identification of claudin-4 as the BFT receptor is presented as enabling development of anti-BFT therapies (abstract language: "opens avenues for the development of anti-BFT therapies").
“opens avenues for the development of anti-BFT therapies”
What this piece can’t prove
  • Summary is based solely on the paper abstract; the abstract does not provide empirical data on therapeutic inhibition of BFT.
  • Cannot assess whether candidate anti-BFT strategies (e.g., antibodies, peptides, small molecules) were tested, or their efficacy/safety, from the provided text.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 40 candidate papers

Candidate

Evolving Symmorphogenic Network Defenses: A Bio-Inspired Framework for Adaptive Cybersecurity Author George White

2026 · Crossref

Source (opens in a new tab)

And 34 more candidates considered.